Inactive Instrument

Neothetics Inc Stock Nasdaq

Equities

US64066G1013

Pharmaceuticals

Sales 2022 16.84 Sales 2023 18.22 Capitalization 1.28M
Net income 2022 -76M Net income 2023 53M EV / Sales 2022 4,528,434 x
Net Debt 2022 68.36M Net Debt 2023 43.37M EV / Sales 2023 2,451,077 x
P/E ratio 2022
-0.05 x
P/E ratio 2023
1.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Neothetics Inc

Managers TitleAgeSince
Chief Executive Officer 54 12-12-31
Director of Finance/CFO 46 18-02-28
Investor Relations Contact - 18-01-31
Members of the board TitleAgeSince
Chief Executive Officer 54 12-12-31
Director/Board Member 56 17-12-31
Director/Board Member 65 17-12-31
More insiders
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing advanced products to address unmet needs in women’s sexual and reproductive health. The Company’s first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Additionally, the Company offers women direct access to Phexxi through its telehealth partner. Using this platform, women can have a telehealth visit with a health care provider (HCP) to determine their eligibility for a Phexxi prescription.
More about the company